ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

587
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
25 Apr 2019 15:29

Viva Biotech IPO: Just About Supporting the Low-End IPO Price Range

Viva Biotech Holdings (1873 HK) is a leading global contract research organisation (CRO). It has launched its IPO to raise net proceeds of HK$1,232...

Logo
791 Views
Share
22 Apr 2019 15:33

Viva Biotech IPO Preview: Show Me the Money

Viva Biotech Shanghai Ltd (1577881D HK) is a leading global contract research organisation (CRO). Viva has started pre-marketing for a Hong Kong...

Logo
722 Views
Share
bullishWuxi Biologics
23 Mar 2019 12:52

ECM Weekly (23 March 2019) - ESR, Sun Car, Ruhnn, CanSino, Frontage, Wuxi Bio, WiseTech,

Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...

Share
bullishWuxi Biologics
20 Mar 2019 18:47

Wuxi Biologics Placement - Past Deals Have Done Well but Progressive Returns Are Getting Lower

Biologics holdings is looking to raise upto US$517m by selling a 4.2% stake in Wuxi Biologics (Cayman) Inc (2269 HK). This will be fourth placement...

Logo
1.2k Views
Share
bullishSmartkarma
30 Jan 2019 10:38
Smartkarma Originals

IPO Analytics: Cut Your Losses and Let Your Profits Run, Holds True for IPOs

Since inception of our IPO research in 2015, the Aequitas Research team has covered over 361 IPOs, which raised over US$100m each, across Asia...

Logo
1.8k Views
Share
x